144 related articles for article (PubMed ID: 38845490)
1. [Is monitoring of anti-factor Xa levels required for low molecular weight heparin prophylaxis of venous thromboembolism in critically ill patients?].
Ding M; Ning Y; Song L; Li P; Xie F; Li S; Wang C
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2024 May; 36(5):461-464. PubMed ID: 38845490
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
[TBL] [Abstract][Full Text] [Related]
3. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin is associated with lower venous thromboembolism events than factor Xa inhibitors in patients with severe blunt trauma: a cohort study from the Trauma Quality Improvement Program.
Chan SY; Huang JF; Cheng CT; Hsu CP; Liao CH; Fu CY
Int J Surg; 2024 Jan; 110(1):280-286. PubMed ID: 37738013
[TBL] [Abstract][Full Text] [Related]
5. Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial.
Wang C; Ning YC; Song LP; Li PJ; Wang FH; Ding MX; Jiang L; Wang M; Pei QQ; Hu SM; Wang H
BMJ Open; 2023 Oct; 13(10):e069742. PubMed ID: 37880168
[TBL] [Abstract][Full Text] [Related]
6. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Yang M; Li J; Sun R; Wang Y; Xu H; Yang B; Wu X; Yu L
J Cancer Res Ther; 2019; 15(7):1541-1546. PubMed ID: 31939435
[TBL] [Abstract][Full Text] [Related]
7. Anti-Xa activity by weight in critically ill patients receiving unfractionated heparin for venous thromboembolism prophylaxis.
Aggarwal MV; Jarrell AS; Gilmore VT; Aboagye JK; Haut ER; Hobson DB; Lau BD; Kickler T; Kraus PS; Shaffer DL; Shermock KM; Streiff MB; Zheng G; Kruer RM
J Crit Care; 2019 Aug; 52():180-185. PubMed ID: 31078999
[TBL] [Abstract][Full Text] [Related]
8. Bariatric venous thromboembolism prophylaxis: an update on the literature.
Hamadi R; Marlow CF; Nassereddine S; Taher A; Finianos A
Expert Rev Hematol; 2019 Sep; 12(9):763-771. PubMed ID: 31219356
[No Abstract] [Full Text] [Related]
9. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review.
Ribic C; Lim W; Cook D; Crowther M
J Crit Care; 2009 Jun; 24(2):197-205. PubMed ID: 19327323
[TBL] [Abstract][Full Text] [Related]
10. Weight-Based Dosing for Low-Molecular-Weight Heparin (Enoxaparin) Administration to Achieve Optimal VTE Prophylaxis in Trauma Patients.
Thind T; Heye T; Henson C; Reif R; Jensen HK; Kalkwarf KJ; Bhavaraju A; Robertson R; Jenkins A
Am Surg; 2024 Jun; 90(6):1406-1411. PubMed ID: 38518208
[TBL] [Abstract][Full Text] [Related]
11. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis.
Wu T; Xia X; Chen W; Fu J; Zhang J
J Clin Pharm Ther; 2020 Aug; 45(4):602-608. PubMed ID: 32449992
[TBL] [Abstract][Full Text] [Related]
12. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
[TBL] [Abstract][Full Text] [Related]
13. Pentasaccharides for the prevention of venous thromboembolism.
Dong K; Song Y; Li X; Ding J; Gao Z; Lu D; Zhu Y
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005134. PubMed ID: 27797404
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis.
Kapoor A; Ellis A; Shaffer N; Gurwitz J; Chandramohan A; Saulino J; Ishak A; Okubanjo T; Michota F; Hylek E; Trikalinos TA
J Thromb Haemost; 2017 Feb; 15(2):284-294. PubMed ID: 28102615
[TBL] [Abstract][Full Text] [Related]
15. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
16. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
Jacobs BN; Cain-Nielsen AH; Jakubus JL; Mikhail JN; Fath JJ; Regenbogen SE; Hemmila MR
J Trauma Acute Care Surg; 2017 Jul; 83(1):151-158. PubMed ID: 28426561
[TBL] [Abstract][Full Text] [Related]
17. Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
Murphy AC; Koshy AN; Farouque O; Yeo B; Raman J; Kearney L; Yudi MB
Heart Lung Circ; 2022 May; 31(5):716-725. PubMed ID: 34896013
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
Lu X; Lin J
BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
[TBL] [Abstract][Full Text] [Related]
19. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Ferrante N; Otten HM; Cuccurullo F; Rutjes AW
Cochrane Database Syst Rev; 2012 Feb; (2):CD008500. PubMed ID: 22336844
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Kreidieh F; Temraz S
Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
